Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

02 Contract Notice

Tender for the Operating Lease of a Surface Plasmon Resonance (SPR) Instrument

  • First published: 04 March 2020
  • Last modified: 06 November 2020
  • Version: N/A
  • This file may not be fully accessible.

  •  

Information icon
You are viewing an expired notice.
Information icon

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
ocds-kuma6s-099500
Published by:
Swansea University
Authority ID:
AA0345
Publication date:
04 March 2020
Deadline date:
05 November 2020
Notice type:
02 Contract Notice
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

the Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for: The advancement of novel epigenetic drugs using cross cutting technology approaches. The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments The generation of novel ADCs effective against ovarian cancer For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation. CPV: 38510000, 33100000, 38000000, 38434540, 39162000, 38510000.

Full notice text

Contract notice

Section I: Contracting authority

I.1) Name and addresses

Swansea University

Procurement - Finance, Swansea University, Singleton Park

Swansea

SA2 8PP

UK

Telephone: +44 1792295890

E-mail: procurement@swansea.ac.uk

NUTS: UKL18

Internet address(es)

Main address: www.swansea.ac.uk

Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0345

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://etenderwales.bravosolution.co.uk/web/login.shtml


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://etenderwales.bravosolution.co.uk/web/login.shtml


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tender for the Operating Lease of a Surface Plasmon Resonance (SPR) Instrument

Reference number: SU122(20)

II.1.2) Main CPV code

38510000

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

the Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for:

The advancement of novel epigenetic drugs using cross cutting technology approaches.

The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments

The generation of novel ADCs effective against ovarian cancer

For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation.

II.1.5) Estimated total value

Value excluding VAT: 280 000.00  GBP

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

33100000

38000000

38434540

39162000

38510000

II.2.3) Place of performance

NUTS code:

UKL18


Main site or place of performance:

Swansea University Singleton campus

II.2.4) Description of the procurement

The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6m GB project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is looking to develop advanced drug technologies for the treatment of ovarian cancer. Building on RBGO success in recent years, CEAT is a collaboration of 6 industrial partners working towards the prevention and treatment of ovarian cancer by embedding enabling technologies and innovation into pre-clinical drug development pipelines for:

The advancement of novel epigenetic drugs using cross cutting technology approaches.

The development of techniques to identify patients that will benefit from targeted epigenetic and non-epigenetic drug treatments

The generation of novel ADCs effective against ovarian cancer.

For antibody development, the SPR detection instrument will be used for early-stage screening of hybridoma/bispecific libraries, to monitor expression and triage antibodies based on binding affinity, profiling binding specificity and providing detailed binding kinetics and affinity to characterisation.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: 280 000.00  GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/04/2020

End: 31/10/2021

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

II.2.14) Additional information

The funding for this purchase covers only the Lease not Purchase of the Equipment. Therefore we are seeking a supplier who can Lease the Equipment detailed within the Tender Specification for the duration of the CEAT project

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents


III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents


III.2) Conditions related to the contract

III.2.2) Contract performance conditions

As detailed within the Tender Specification for the Lease not Purchase of the equipment detailed for the project duration

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 02/04/2020

Local time: 12:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date: 02/04/2020

Local time: 12:00

Place:

Swansea University Procurement

Information about authorised persons and opening procedure:

BravoSolution itt 80280

Sue Davies MCIPS MSc, Category Manager

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) Additional information

The funding for this equipment is for the Lease not Purchase of the detailed equipment, for the duration of the CEAT project up to 31st October 2021

NOTE: The authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at https://www.sell2wales.gov.wales/search/search_switch.aspx?ID=99500

(WA Ref:99500)

The buyer considers that this contract is suitable for consortia.

VI.4) Procedures for review

VI.4.1) Review body

High Court

Royal Courts of Justice, The Strand

London

WC2A 2LL

UK

Telephone: +44 2079477501

VI.5) Date of dispatch of this notice

02/03/2020

Coding

Commodity categories

ID Title Parent category
38434540 Biomedical equipment Analysers
39162000 Educational equipment School furniture
38000000 Laboratory, optical and precision equipments (excl. glasses) Technology and Equipment
33100000 Medical equipments Medical equipments, pharmaceuticals and personal care products
38510000 Microscopes Checking and testing apparatus

Delivery locations

ID Description
1017 Bridgend and Neath Port Talbot
1018 Swansea

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

Document family

Notice details
Publication date:
04 March 2020
Deadline date:
05 November 2020 00:00
Notice type:
02 Contract Notice
Authority name:
Swansea University
Publication date:
09 November 2020
Notice type:
03 Contract Award Notice - Incomplete Procedure
Authority name:
Swansea University

About the buyer

Main contact:
procurement@swansea.ac.uk
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
06/11/2020 15:12
Notice Cancelled
This notice has been cancelled. The original deadline date of 02/04/2020 is no longer applicable.

Please note that due to funding issues, this lease tender has been cancelled without award. However a fresh tender for the purchase of equipment will be published in the next fortnight, with an OJEU Contract Notice and new Bravo ITT.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.